S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Why Wall Street Loves These 3 Penny Stocks
The gold catalyst we’ve waited for (Ad)
3 Leading Dividend Stocks Expected To Grow Earnings
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
The gold catalyst we’ve waited for (Ad)
Closing prices for crude oil, gold and other commodities
Low Volume Bunge Plunge Presents an Opportunity
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
KB Home Strong Results Lift Prices
Carvana May Be Able To Reach Profitability This Year
S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Why Wall Street Loves These 3 Penny Stocks
The gold catalyst we’ve waited for (Ad)
3 Leading Dividend Stocks Expected To Grow Earnings
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
The gold catalyst we’ve waited for (Ad)
Closing prices for crude oil, gold and other commodities
Low Volume Bunge Plunge Presents an Opportunity
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
KB Home Strong Results Lift Prices
Carvana May Be Able To Reach Profitability This Year
S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Why Wall Street Loves These 3 Penny Stocks
The gold catalyst we’ve waited for (Ad)
3 Leading Dividend Stocks Expected To Grow Earnings
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
The gold catalyst we’ve waited for (Ad)
Closing prices for crude oil, gold and other commodities
Low Volume Bunge Plunge Presents an Opportunity
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
KB Home Strong Results Lift Prices
Carvana May Be Able To Reach Profitability This Year
S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Why Wall Street Loves These 3 Penny Stocks
The gold catalyst we’ve waited for (Ad)
3 Leading Dividend Stocks Expected To Grow Earnings
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
The gold catalyst we’ve waited for (Ad)
Closing prices for crude oil, gold and other commodities
Low Volume Bunge Plunge Presents an Opportunity
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
KB Home Strong Results Lift Prices
Carvana May Be Able To Reach Profitability This Year
NASDAQ:NAUT

Nautilus Biotechnology - NAUT Stock Forecast, Price & News

$2.41
-0.07 (-2.82%)
(As of 03/23/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.36
$2.53
50-Day Range
$1.79
$2.64
52-Week Range
$1.50
$5.07
Volume
76,594 shs
Average Volume
134,187 shs
Market Capitalization
$300.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

Nautilus Biotechnology MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
66.0% Upside
$4.00 Price Target
Short Interest
Healthy
1.80% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.71) to ($0.72) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.98 out of 5 stars

Medical Sector

573rd out of 986 stocks

Analytical Instruments Industry

18th out of 28 stocks


NAUT stock logo

About Nautilus Biotechnology (NASDAQ:NAUT) Stock

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.

Receive NAUT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nautilus Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

NAUT Stock News Headlines

My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
NAUT Nautilus Biotechnology, Inc.
Recap: Nautilus Biotechnology Q3 Earnings
The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
Nautilus Biotechnology Q2 2022 Earnings Preview
Nautilus Biotechnology Q1 2022 Earnings Preview
Nautilus Biotechnology GAAP EPS of -$0.13 in-line
Nautilus Biotechnology Q4 2021 Earnings Preview
See More Headlines
Receive NAUT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nautilus Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

NAUT Company Calendar

Last Earnings
2/23/2023
Today
3/23/2023
Next Earnings (Estimated)
5/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NAUT
Fax
N/A
Employees
113
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+66.0%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-57,920,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.53 per share

Miscellaneous

Free Float
73,296,000
Market Cap
$300.94 million
Optionable
Optionable
Beta
0.78

Key Executives

  • Mr. Sujal M. PatelMr. Sujal M. Patel (Age 48)
    Co-Founder, CEO, Pres, Sec. & Director
    Comp: $652k
  • Dr. Parag Mallick Ph.D. (Age 46)
    Co-Founder, Chief Scientist & Director
    Comp: $497.55k
  • Mr. Matthew B. Murphy ESQ.Mr. Matthew B. Murphy ESQ. (Age 58)
    Gen. Counsel
    Comp: $382.64k
  • Ms. Anna  MowryMs. Anna Mowry
    CFO & Treasurer
  • Ms. Mary E. Godwin (Age 64)
    Sr. VP of Operations
  • Mr. Chris Blessington
    VP of Corp. Marketing & Communications
  • Ms. Gwen E. Weld (Age 65)
    Chief People Officer
  • Mr. Nick A. Nelson (Age 40)
    Chief Bus. Officer & Sr. VP of Bus. Devel.
  • Dr. Subra Sankar Ph.D. (Age 64)
    Sr. VP of Product Devel.













NAUT Stock - Frequently Asked Questions

Should I buy or sell Nautilus Biotechnology stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nautilus Biotechnology in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NAUT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NAUT, but not buy additional shares or sell existing shares.
View NAUT analyst ratings
or view top-rated stocks.

What is Nautilus Biotechnology's stock price forecast for 2023?

2 brokers have issued 12-month price objectives for Nautilus Biotechnology's stock. Their NAUT share price forecasts range from $2.00 to $6.00. On average, they expect the company's share price to reach $4.00 in the next year. This suggests a possible upside of 66.0% from the stock's current price.
View analysts price targets for NAUT
or view top-rated stocks among Wall Street analysts.

How have NAUT shares performed in 2023?

Nautilus Biotechnology's stock was trading at $1.80 at the start of the year. Since then, NAUT shares have increased by 33.9% and is now trading at $2.41.
View the best growth stocks for 2023 here
.

Are investors shorting Nautilus Biotechnology?

Nautilus Biotechnology saw a decline in short interest in February. As of February 28th, there was short interest totaling 894,200 shares, a decline of 40.4% from the February 13th total of 1,500,000 shares. Based on an average trading volume of 138,400 shares, the short-interest ratio is presently 6.5 days. Approximately 1.8% of the shares of the company are short sold.
View Nautilus Biotechnology's Short Interest
.

When is Nautilus Biotechnology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023.
View our NAUT earnings forecast
.

How were Nautilus Biotechnology's earnings last quarter?

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) issued its earnings results on Thursday, February, 23rd. The company reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.15) by $0.04.

What is Nautilus Biotechnology's stock symbol?

Nautilus Biotechnology trades on the NASDAQ under the ticker symbol "NAUT."

Who are Nautilus Biotechnology's major shareholders?

Nautilus Biotechnology's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (0.77%), Clarius Group LLC (0.47%), Morgan Stanley (0.30%), Nantahala Capital Management LLC (0.23%), Sentinel Trust Co. LBA (0.15%) and Renaissance Technologies LLC (0.08%). Insiders that own company stock include Anna Mowry, Gwen E Weld, Life Sciences Maste Perceptive, Matthew B Murphy, Matthew L Posard, Matthew S Mcilwain, Perceptive Advisors Llc, Subramanian Sankar and Sujal M Patel.
View institutional ownership trends
.

How do I buy shares of Nautilus Biotechnology?

Shares of NAUT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nautilus Biotechnology's stock price today?

One share of NAUT stock can currently be purchased for approximately $2.41.

How much money does Nautilus Biotechnology make?

Nautilus Biotechnology (NASDAQ:NAUT) has a market capitalization of $300.94 million. The company earns $-57,920,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis.

How many employees does Nautilus Biotechnology have?

The company employs 113 workers across the globe.

How can I contact Nautilus Biotechnology?

Nautilus Biotechnology's mailing address is 51 ASTOR PLACE 10TH FLOOR, NEW YORK NY, 10003. The official website for the company is www.nautilus.bio. The company can be reached via phone at 206-333-2001 or via email at investorrelations@nautilus.bio.

This page (NASDAQ:NAUT) was last updated on 3/24/2023 by MarketBeat.com Staff